Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model

Published

on

NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™ early-stage risk assessment testing and care management program across primary care and specialty clinician networks under a real-world evidence development program for patients with diabetic kidney disease (DKD). KidneyIntelX enables a shift in focus from care coordination efforts focused on Mount Sinai’s late-stage kidney disease patients to a focus on patients with early stages of the disease where prognosis and treatment with population health care navigation assistance can improve patient care and outcomes and generate cost savings. Before the end of 2021, Mount Sinai expects to provide KidneyIntelX testing and downstream care management at a rate of 300 patients per week with approximately 6,000 eligible patients tested by calendar Q2 2022 under this development program.

In an initial rollout across seven primary care practices in Manhattan, New York City, the KidneyIntelX program has demonstrated value for clinical care delivery by identifying patients with DKD at low, intermediate, and high risk of declining kidney function or kidney failure early in the disease lifecycle when treatment has the potential for maximum effect. KidneyIntelX access is now expected to grow to over 300 treating physicians in calendar Q4 2021. The number of eligible patients who have scheduled physician interaction with active electronic health record access to KidneyIntelX is expected to grow up to sixfold in the same period.

“Our KidneyIntelX enabled diabetic kidney disease program allows us to provide a high standard of care in early-stage kidney disease patients where we have the best chance to help patients avoid significant kidney damage,” said Robert Fields, MD, MHA, Executive Vice President and Chief Population Health Officer at Mount Sinai Health System. “Ongoing analysis and sharing of doctor and patient user experience combined with population level data insights is helping to drive systemwide access to early-stage risk-assessment and treatment.”

“Systematically identifying high-risk patients with DKD under primary care at the earliest stages of their disease is essential for improving outcomes, quality of life, and reducing health care cost in the population with kidney disease,” said David C. Thomas, MD, Professor of Medicine, Medical Education and Rehabilitation and Human Performance and Interim System Chair, Department of Medicine, Icahn School of Medicine at Mount Sinai. “We now have the tools, including care navigation, and pharmacy and dietician support, in place to do more than manage the transition to dialysis or transplant. We believe this program will enable advanced support for our primary care teams to help improve the long-term outlook and quality of life for our patients with diabetic kidney disease.”

In 2021, Mount Sinai’s KidneyIntelX enabled care program has achieved significant milestones, including successful integration into the clinical workflow across the Health System’s network of primary care and specialty physician practices. Early results of the real-world evidence program are aligned with published utility study data. These results indicate that appropriate pharmacy management and specialist referrals are more likely when KidneyIntelX testing is integrated into the care plan. These actions are important for slowing the progression of DKD. Under Mount Sinai’s population health guided care model, primary care physicians can receive direct test ordering, education and advanced pharmacy, dietary and specialist support information for their DKD patients. 

KidneyIntelX includes technology that was initially developed by Mount Sinai faculty. This technology has been licensed by Mount Sinai to Renalytix. Mount Sinai and a small number of Mount Sinai faculty inventors have a financial interest in Renalytix. Mount Sinai also has representation on the Renalytix Board of Directors.

About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product is KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked in U.S. News & World Report’s “Honor Roll” of the top 20 U.S. hospitals and among the top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Urology, and Rehabilitation. Mount Sinai Kravis Children’s Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked among the Top 20 nationally for ophthalmology. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and “The World’s Best Specialized Hospitals” ranks Mount Sinai Heart as No. 1 in New York and No. 5 globally and the Division of Gastroenterology as No. 5 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the commercial prospects of KidneyIntelX, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, the rate of testing with KidneyIntelX in health care systems, expectations and timing of announcement of real-world testing evidence, the potential for KidneyIntelX to be approved for additional indications, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 28, 2020, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

US Investor Contact:

Media Contacts:
United States:
Jennifer Moritz
Zer0 to 5ive for Renalytix
(917) 748-4006
[email protected]

Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Cawthorne
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893 / 07584 391 303

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects

Published

on

metabolon-now-includes-spectral-data-files-for-all-global-discovery-panel-projects

MORRISVILLE, N.C., May 28, 2024 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the availability of spectral data files as an option for Global Discovery Panel projects, providing clients with an enhanced level of detail and transparency in metabolomics analysis. The addition of spectral data further complements Metabolon’s robust suite of metabolomics offerings, including the largest Level 1 library of metabolites, an advanced bioinformatics platform, and expert scientific support.

Spectral data is the initial data generated during a mass spectrometry (MS)- based metabolomic analysis. Spectral data contains a wealth of information about the metabolites present in a sample, including their chemical structure, concentration, and interactions with other molecules. Metabolon facilitates further exploration of the dark metabolome and validation of findings by offering spectral data files as an option with Global Discovery Panel projects. These data should enable the discovery of unique metabolites and biomarkers.
“The availability of spectral data enhancement not only provides clients with a more comprehensive view of their metabolomics data but also reinforces our commitment to transparency and delivering unparalleled value to our clients,” said Ro Hastie, CEO at Metabolon.
This significant update underscores Metabolon’s commitment to providing comprehensive and actionable insights to empower scientific discoveries and drive advancements in healthcare and multiomics research. Visit https://www.metabolon.com/ to learn more about how Metabolon deciphers thousands of discrete chemical signals to discover biomarkers and reveal biological pathways.
About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.  Metabolon’s Global Discovery Panel is enabled by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
About MetabolomicsMetabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Logo – https://mma.prnewswire.com/media/1671125/Metabolon_Inc_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/metabolon-now-includes-spectral-data-files-for-all-global-discovery-panel-projects-302156728.html

Continue Reading

Artificial Intelligence

Caseware Introduces AiDA: The AI-Powered Digital Assistant Changing the Face of Accounting and Audit

Published

on

caseware-introduces-aida:-the-ai-powered-digital-assistant-changing-the-face-of-accounting-and-audit

TORONTO, May 28, 2024 /PRNewswire/ — Caseware International, a global leader in cloud-enabled audit, financial reporting and data analytics solutions, is delighted to announce the pre-launch availability of Caseware AiDA, its Artificial Intelligence digital assistant. As the latest enhancement to the industry-leading Caseware Cloud platform, AiDA complements Caseware’s comprehensive suite of solutions created with accounting, audit and finance professionals in mind.

AiDA is designed to enhance efficiency, ensure compliance and provide precise, context-aware responses to profession-specific enquiries enabling accounting, audit and finance experts to work more efficiently, collaborate with greater effectiveness and gain deeper insights.
Whether providing timely responses to methodology or compliance questions, supporting the processing and analysis of audit evidence, or assisting with the production of key audit workpapers and deliverables, AiDA empowers professional users to achieve more with less effort. This will, in turn, drive practice growth and power the financial success of clients.
David Osborne, Chief Executive Officer at Caseware International remarked, “Caseware AiDA is the future. Our vision is to place powerful tools in the hands of our clients, enabling them to do their work better than they have ever done before. This release is just the beginning of a wave of innovation in AI and it demonstrates the focus we have on our accelerated roadmap to build out our offering on the Caseware Cloud platform. Caseware AiDA offers powerful digital assistance to accountants and is further proof of the ways in which Caseware is underpinning the relevance of the profession.”
Some of the benefits to be gained from Caseware AiDA include:
Enhanced workflow efficiency with precision and relevance – whether summarizing lengthy PDFs or providing informed answers about your documentation in the moment, AiDA helps you work smarter, not harder.Reassurance around security and compliance – with AiDA, no prompts are stored or fed back into the model. Users can trust AiDA to maintain the highest data security and compliance standards that Caseware has always delivered for the profession.Assistance with routine tasks – AiDA assists with mundane tasks, enabling professionals to focus on strategic decision-making.Focus on quality output – AiDA delivers a safe and fit-for-purpose resource which ensures efficient workflows for clients.Feedback on AiDA has underscored the demand for tailored, secure AI solutions in professional environments. Danielle Supkis Cheek, VP, Head of Analytics and AI at Caseware International commented, “We recently showcased AiDA to a number of clients beyond our beta phase community at Caseware’s 2024 North American User Group. The response was phenomenal and, in line with our roadmap, we’re excited to continue to enhance AiDA based on user feedback and technological advancements.”
Currently available to Caseware Cloud customers in the United States for early access, AiDA will ultimately be available across the globe and, specifically, in Australia, Canada and Europe later this year. Soon, AiDA will be a core component of all cloud-enabled solutions, across all regions. AiDA’s capabilities are constantly evolving, including better context awareness in document interactions and more extensive support for multilingual queries. AiDA is set to transform how professionals in the accounting and audit fields manage their tasks, offering unparalleled support and efficiency.
Caseware AiDA (pronounced AY-duh) draws inspiration from Ada Lovelace, whose impact on scientific computing continues to influence generations of technologists and mathematicians around the world.
Caseware encourages users to explore AiDA’s features and experience the future of digital assistance. To see AiDA in action, join us at ENGAGE at the ARIA Resort & Casino from June 3-6 or sign up to hear more from Danielle Supkis Cheek at the Streamlining Audits with AI: Efficiency and Quality Gains webinar taking place at 11:00 AM ET on July, 18.
About Caseware InternationalCaseware is the leading global provider of desktop and cloud-enabled solutions for audit, assurance, financial reporting and data analytics for accounting firms, corporations, and government regulators. Caseware’s innovative tools and platforms help more than half a million customers in 130 countries work smarter, dig deeper and see further as they transform insights into impact. For more information, visit www.caseware.com.
 
Notes to editorsIn the event of media enquiries, please contact:Jill QuinnDirector of Corporate CommunicationsCaseware [email protected]
Photo – https://mma.prnewswire.com/media/2421134/CaseWare_International_Inc__Caseware_Introduces_AiDA__The_AI_Pow.jpg
Photo – https://mma.prnewswire.com/media/2421135/CaseWare_International_Inc__Caseware_Introduces_AiDA__The_AI_Pow.jpg

View original content:https://www.prnewswire.co.uk/news-releases/caseware-introduces-aida-the-ai-powered-digital-assistant-changing-the-face-of-accounting-and-audit-302155473.html

Continue Reading

Artificial Intelligence

LONGi announces the “Lighthouse Project” to expand the agile intelligent manufacturing to more of its own production bases across the globe

Published

on

longi-announces-the-“lighthouse-project”-to-expand-the-agile-intelligent-manufacturing-to-more-of-its-own-production-bases-across-the-globe

JIAXING, China, May 28, 2024 /PRNewswire/ — On May 23rd, LONGi Green Energy Technology Co., Ltd. (hereinafter referred to as “LONGi “), a global leader in solar technology, officially announced the “Lighthouse Project”, which will continue to rapidly expand the agile intelligent manufacturing model of LONGi’s Jiaxing Lighthouse Factory to more production and manufacturing bases, achieving a comprehensive upgrade of production intelligent manufacturing capabilities. This sets a digitalization benchmark for high-quality development in the PV industry and leads the way forward.

The first “Lighthouse Factory” in the global PV industry – LONGi’s Jiaxing Production Base, lifted the mysterious veil for the public. An experience group composed of industry experts, customer representatives, and media journalists became the first visitors to LONGi’s Jiaxing Lighthouse Factory, immersing themselves in the production line and experiencing the charm of “Lighthouse Factory” intelligent manufacturing.
Established in 2020, LONGi’s Jiaxing Production Base mainly produces LONGi’s BC (Back-Contact) series of high-efficiency solar modules. It has Phase I, II, and III factories, covering a total area of more than 1,300 acres, with 51 intelligent production lines and an overall module production capacity exceeding 35GW, making it one of the largest industrial clusters in the industry.
On December 14, 2023, the World Economic Forum (WEF) released a new batch of “Lighthouse Network” lists, and LONGi’s Jiaxing Production Base was the only factory in the global PV industry to be included. This signifies that LONGi’s achievements in intelligent manufacturing and digitalization are leading globally, becoming a representative of advanced manufacturing, and the first global “Lighthouse Factory” in the PV industry has attracted much attention.
During this close-up experience at LONGi’s Jiaxing Lighthouse Factory, all members of the experience group expressed their shock and unprecedentedly felt the disruptive upgrade of AI intelligence to traditional industry. The innovation of LONGi’s Jiaxing Lighthouse Factory is not only in the transformation of production line automation and intelligence but also in the reconstruction of production relations. AI intelligence has become the brain of production management, continuously innovating autonomously based on big data models, achieving a truly meaningful intelligent manufacturing upgrade and self-driving force, and safeguarding quality and efficiency.
LONGi’s Jiaxing Lighthouse Factory has built over 30 digital use cases, achieving a 43% increase in product quality reliability, an 84% reduction in product production and delivery cycle, and a 20% reduction in overall unit energy consumption at the base, becoming a model of high-quality development in the photovoltaic industry.
The most core aspect of LONGi’s Jiaxing Lighthouse Factory is the five major coolest technologies. AI intelligent distribution of solar cells realizes precise delivery of customer needs, ensuring efficient production by intelligently optimizing daily production plans. More flexible automation in production ensures the standardization of each link in the module production process, fully meeting the customized scene requirements of customers. AI quality inspection throughout the entire life cycle of product production leaves no place for quality hazards, ensuring the quality of the product is as solid as a rock. The end-to-end delivery system has reconstructed the intelligent management of order production and delivery cycles, achieving rapid and high-quality satisfaction of customer product needs. Intelligent human resource management has greatly improved production efficiency while enhancing the innovation of employees, transforming each excellent skill and experience into data, continuously optimizing skills and management autonomously, ensuring the optimal arrangement of order demands and human resources, and effectively guaranteeing high-quality product output.
The combination of artificial intelligence, big data, cloud platforms, and industrial muscles is the four elements that make LONGi’s Jiaxing Lighthouse Factory successful, and also the core of LONGi’s intelligent manufacturing. LONGi’s BC (Back-Contact) full-scene products have also reached a new level under the support of LONGi’s intelligent manufacturing. The reason why TaiRay silicon wafers, HPBC2.0, Hi-MO 9, Hi-MO X6 Max, and other major products have concentrated on explosions this year is due to LONGi’s intelligent manufacturing’s absolute satisfaction in understanding customer needs.
LONGi’s Vice President Zhang Haimeng said in his keynote speech: Since the official announcement of BC (Back-Contact) technology last September, LONGi has released multiple new scene-based module products. Whether it is anti-dust accumulation or heat and humidity resistance, the core purpose is to meet the customized needs of customers through differentiated innovation. All of this is inseparable from the confidence in production strength brought by LONGi’s intelligent manufacturing, and it is also the strong support of LONGi’s intelligent manufacturing that has truly implemented “customer-centric.”
During the panel session of the day, Hu Zhifeng, Head of Intelligent Manufacturing Department, Module Manufacturing Center of LONGi, revealed that the newly launched Hi-MO X6 Max modules will be officially put into production at LONGi’s Jiaxing Lighthouse Factory in the near future. With the help of digital and intelligent means, product quality is improved, and energy consumption is reduced. “Use the most advanced production technology to achieve the highest level of technical products and create higher value for customers.”
LONGi has always adhered to the core value of customer value, providing customers with high-value and reliable products as its own responsibility, continuously exploring new paths for the clean energy industry, from efficiency research and development to product and solution scenario, from traditional manufacturing to intelligent manufacturing driven by digitalization, step by step towards a green energy world, leading the global energy transition with LONGi’s intelligent manufacturing.
About LONGi
Founded in 2000, LONGi is committed to being the world’s leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation.
Under its mission of ‘making the best of solar energy to build a green world’, LONGi has dedicated itself to technology innovation and established five business sectors, covering mono silicon wafers cells and modules, commercial & industrial distributed solar solutions, green energy solutions and hydrogen equipment. The company has honed its capabilities to provide green energy and has more recently, also embraced green hydrogen products and solutions to support global zero carbon development. www.longi.com 
Photo – https://mma.prnewswire.com/media/2422491/LONGi_announces__Lighthouse_Project__expand_agile_intelligent_manufacturing_production_bases.jpgPhoto – https://mma.prnewswire.com/media/2422492/LONGi_announces__Lighthouse_Project__expand_agile_intelligent_manufacturing_production_bases.jpgLogo – https://mma.prnewswire.com/media/1606520/LONGi_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/longi-announces-the-lighthouse-project-to-expand-the-agile-intelligent-manufacturing-to-more-of-its-own-production-bases-across-the-globe-302156707.html

Continue Reading

Trending